Autoimmune diseases in patients and animal models are reviewed from the standpoint of immunoregulatory defects which predispose to autoimmunity. New information is provided about autoantibodies which indicates, on the basis of idiotypic cross-reactivity, that they may be closer to normal antibodies than previously thought. The importance of estrogens as a predisposing factor and androgens as a protective factor is discussed in relation to modulation ofimmune response by sex hormones. Similarities between autoimmune diseases and Acquired Immunodeficiency Syndrome (AIDS) are presented and new therapeutic approaches are discussed.
INTRODUCTION
Autoimmunity is traditionally defined as the body's immune system turning against itself to produce lymphocytes reactive with self components (2-5). These lymphocytes may be B cells secreting autoantibodies like those responsible for hemolytic anemia, T cells attacking and destroying target organs such as the thyroid, or most often, a combination of both.
The old concept that individuals are tolerant to self because ofthe elimination of "forbidden" clones during fetal development was abandoned almost a decade ago. Normal, healthy individuals have B lymphocytes capable of reacting with self antigens through Ig receptors. Such cells can be triggered to proliferate and secrete autoantibodies in a wide range of specificities. This potential for autoimmunity exists in everyone and becomes manifest rather frequently. Examples are drug-induced autoimmunity, autoimmunity associated with aging, and the autoimmunity that occurs in chronic infectious diseases. Why autoimmunity doesn't occur still more often is generally explained by the actions of an appropriately balanced immunoregulatory system that normally functions to mount brisk immune responses to foreign antigens and to prevent reactions to self. But exactly how immunoregulation works in all of its intricacies and mechanisms has become a very complicated problem.
Ten years ago we simply attributed regulation to an equilibrium established between helper (OKT4) and suppressor (OKTS) T cells. Autoimmune patients and autoimmune mice were found to be deficient in suppressor function and to manifest polyclonal B cell activation. However, we now appreciate that this idealized situation is not always found and that there is a poor correlation between the number and function of suppressor T cells and autoimmune disease activity.
IMMUNOREGULATION AND AUTOIMMUNITY T cell activation requires appropriate presentation of antigen on the surface of an antigen presenting cell (APC), usually a macrophage strongly expressive of class I1 histocompatability cell surface antigens ( Fig. 1 ). These cell surface molecules, collectively called Ia (or DR in man), are now known to be the products of several IR gene loci in the Major Histocompatibility Complex (MHC) (I-A and I-E in the mouse; DP, DQ and DR in man). The Ia molecules are capable of functionally, perhaps physically, interacting with foreign antigens to activate T cells in conjunction with the secretion of the macrophage product interleukin-1 (IL-1).
Studies at both the gene level and at the cell sur- IL-1 and to antigen on APCs ( Fig. 1) to produce interleukin-2 (IG2), a critical immune hormone that interacts with specific receptors on T cells and natural killer (NK) cells to mediate lymphocyte proliferation, y interferon production and the production of other lymphokines that regulate B cells (e.g., B cell growth and differentiation factors). The polyclonal B cell activation that occurs in autoimmunity probably arises from multiple mechanisms, some dependent and some independent of T cells and IL-2. Indeed, IL-2 production and response is deficient in many autoimmune conditions. Recent studies have shown that the T cell antigen receptor is also composed of two chains (a and B) and is structurally homologous to both immunoglobulin and HLA. All three families of molecules are thought to derive from a single primordial gene product through an evolutionary process of gene duplication and mutation. The T cell receptor expresses idiotype and binds both Ia and antigen. The outcome of this binding is extremely important for normal immunoregulation or for autoimmunity. For example, normal individuals who are HLA-Bg-DR3 have evidence of immunologic hyperresponsiveness as evidenced by studies of humoral and cellular immunity. Whether this IR gene effect is exerted at the level of the antigen presenting.cel1 or at the level of the responding T cell is not yet known.
Gamma interferon induces the expression of class I1 molecules on APCs and has been postulated as the cause of aberrant Ia expression on thyroid cells in thyroiditis. Such expression could convert parenchymal cells into APCs which might then lead to aberrant immune reactions locally and target-organ specific autoimmunity. A local virus infection has been proposed as the stimulus for this interferon production.
Autoantibodies. Autoantibodies, like myeloma proteins, were once considered highly abnormal B cell products. We now appreciate that both autoantibodies and myeloma proteins are rather conventional Igs that can teach us much about normal immune mechanisms. Myelomas are overproduced and autoantibodies have unconventional specificities, but beyond that they seem rather ordinary.
Antibodies to DNA occur in the majority of lupus patients but are difficult to induce in experimental animals. Several monoclonal macroglobulins which react with Klebsiella polysaccharides also share idiotypic determinants with monoclonal lupus anti-DNA autoantibodies and have similar polynucIeotide-binding properties. The reaction with the polynucleotides is specifically inhibited by Klebsiella polysaccharides, which also inhibit binding to the anti-idiotype. This idiotype is thought to derive TOXICOLOGIC PATHOLOGY from a single germ line gene whose original specificity is probably not anti-DNA, but anti-bacterial.
In another instance, a single amino acid substitution arising as a mutation in a monoclonal antibody to polyphorylcholine (a constituent of the pneumococcus) resulted in a loss of the original specificity and acquisition of reactivity with DNA and cardiolipin, features characteristic of anti-DNA antibodies in lupus. These studies, taken together, suggest that autoantibodies such as anti-DNA may arise through a process of somatic mutation from an original antibody whose specificity might be antibacterial or anti-viral.
A dominant cross-reactive idiotype has recently been reported both in lupus patients and in a majority of healthy family members of these patients who did not bind DNA. Thus, the idiotype and the DNA-binding site represent different epitopes on the Ig molecule in these individuals. Again, somatic mutation might be responsible for the acquisition of anti-DNA specificity in the lupus patients.
Sex Horitiones. Autoimmune diseases are much more common in women that in men (1) . Normal females are more immunologically reactive than normal males and are thought, therefore, to be more susceptible to autoimmune disorders. These observations are explained by the ability of sex steroid hormones to modulate immune reactivity, with androgens suppressing and estrogens augmenting. This area of study began with studies performed in the classic B/W mouse model for lupus, in which female mice develop autoantibodies, immune complex glomerulonephritis, and die from renal failure several months earlier than males. Male B/W mice that have been castrated prior to puberty develop an accelerated disease that is indistinguishable from the one seen in females. Although gonadectomy does not benefit female B/W mice, the administration of male hormone suppresses their disease and allows them to live a normal life span. Most importantly, this beneficial effect of androgen can be demonstrated as late as six months of age, a time when SLE is already well established in female B/W mice.
These studies have their clinical counterpart in SLE, where there is a deviation in the normal metabolism of estradiol resulting in an elevation of estrogenic metabolites and the creation of a hyperestrogenic state. There is also evidence for decreased total androgens in SLE, so that sex hormone factors are now considered important in the pathogenesis of autoimmune disease.
Both SLE patients and mice demonstrate a delayed clearance of particulate immune complexes. Female B/W mice develop this abnormality earlier than males, but it can be suppressed in female B/W mice by exposing them to sustained androgen. In 
Polyclonal B cell activation Immune complexes Increased serum beta-2-microglobulin Acid labile interferon Decreased autologous mixed lymphocyte response Decreased interleukin-2 Decreased natural killer cells
contrast, defective clearance develops earlier in male B/W mice given sustained estrogen. These results suggest that sex steroid hormones have an important influence on the clearance of immune complexes, and offer an explanation for the clinical benefit achieved in mice by androgen administration.
There is evidence for sex steroid hormone receptors in the lymphoid organs of both humans and mice. Moreover, sex hormones act to influence lymphocyte number and function. The OKT8 suppressor cells in man and the Lyt-2' suppressor cells in mice are important target sites for sex hormone modulation. Estrogen depleted Lyt-2+ cells, whereas testosterone increased or maintained this subpopulation of cells i n spleen and lymph nodes. Similarly, the suppressor cell activity and IL-2 production on a per cell basis in .estrogen-treated animals was diminished, whereas testosterone-treated animals had normal or enhanced activity.
Lessons froin AIDS. The Acquired Immunodeficiency Syndrome (AIDS) has many lessons for autoimmunity. It is now firmly established that the human T Cell Leukemia Virus Type 111, which is specifically cytopathic for OKT4 helper cells, is the cause of AIDS. There are many immunologic similarities between AIDS and SLE, including polyclonal B cell activation, serum immune complexes, increased serum ~-2-microglobulin, acid-labile interferon, decreased AMLR, IL-2 and natural killer cell activity (Table I) . The active research and therapeutic trials being conducted in AIDS patients may soon yield information important also for other autoimmune patients.
Lessoris front Miirine Models of SLE. For over two decades, certain inbred strains of mice genetically susceptible to generalized autoimmune disease resembling SLE have been invaluable models for study (6) . The lessons learned from these animals (Table 111 ) indicate the complexity of the problem. There is no H2 or allotype association; there is only evidence for genetic heterogeneity among the several available strains. There is also an excessive Ia expression in the Ipr mice. Sex hormones play an accelerating role in the female-predominant disease of B/W mice, and the Y chromosome has an ac- Table 11 .
NEW THERAPEUTIC APPROACHES
The current biological revolution is bringing not only conceptual advances, but also possibilities for new therapeutic interventions. To date, these therapeutic strategies have been tried predominantly in animal models of autoimmunity (except as indicated in Table 111 ). Monoclonal anti-Ia antibodies may act by interfering with cellular interactions involving Class I1 molecules, and have proved successful in several animal models. Monoclonal anti-idiotypic antibody specific for anti-DNA is less successful because of the emergence of private idiotypes which may be a significant problem with this potential form of therapy. Attenuated T cell lines specific for experimental autoimmune encephalomyelitis or arthritis have been used to vaccinate and protect against disease.
Antibodies to the L3T4 molecule of helper T cells have proved beneficial in murine lupus and allergic encephalomyelitis. This is an interesting refinement from older work with non-specific anti-lymphocyte antibodies. Total lymphoid irradiation, a treatment used in Hodgkin's Disease; has been tried successfully in a small number of patients with RA and SLE. It appears to deplete helper function, and it induces a non-specific suppressor. General biologic approaches, such as androgen suppression or dietary manipulation, have been very successful in animal models. The attenuated androgen danazol has been used therapeutically in idiopathic thrombocytopenic purpura, with some success. Fish oil fatty acids appear to interfere with arachidonic acid pathways, and to suppress inflammation.
Immunopharmacologic approaches, including interferon and IL-2, have had disappointing results in AIDS patients. A variety of immunomodulating drugs are under development. Cyclosporin, a drug established as useful in transplantation, is being tried in autoimmune disease, but its toxicity could be a problem.
